Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: Conference, Product/Service, Trade Show

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024


Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data from the company's SPRINT (SARS-Cov-2 PRotease INhibitor Treatment) study of EDP-235 has been accepted for a poster presentation at ESCMID Global 2024 (formerly ECCMID) being held April 27?30 in Barcelona, Spain.

The poster presentation includes primary and post-hoc analyses from the double-blind, placebo-controlled Phase 2 clinical trial of EDP-235, a 3CL protease inhibitor, in non-hospitalized, symptomatic adults with mild or moderate COVID-19 who were not at high risk for severe disease.

Poster Title: "Efficacy and Safety of EDP-235 in Non-Hospitalized Adults with Mild or Moderate COVID-19: Results from the Phase 2 SPRINT Study"
Abstract Number: 02980
Poster Number: PO423
Day: April 27, 2024
Time: 12:00 p.m. CEST / 6:00 a.m. ET
Session Location: Poster Area
Session Title: COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)
Presenter: Scott T. Rottinghaus, M.D., Chief Medical Officer, Enanta Pharmaceuticals, Inc.

The scientific program for ESCMID Global 2024 can be found at https://www.eccmid.org/scientific-programme

About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta's research and development programs are currently focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU) and the company has previously advanced clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic hepatitis B virus (HBV) infection.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis C virus infection (HCV) and is sold by AbbVie in numerous countries under the trade names MAVYRET®(U.S.) and MAVIRET®(ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta's royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie contribute ongoing funding to Enanta's operations. Please visit http://www.enanta.com for more information.


These press releases may also interest you

at 07:00
Ahead of Sunday's Big Game, Instacart is enlisting extra help on game day grocery deliveries throughout Kansas City. Instacart's first-ever Super Bowl commercial is transforming into an incredible live event ? get ready to witness a grocery delivery...

at 06:00
Groceries delivered in Oscar Mayer Wienermobile by Green Giant, Cheetos® Chester Cheetah®, The Kool-Aid Man, and The Pillsbury Doughboytm PHILADELPHIA, Feb. 8, 2025 /PRNewswire/ -- Ahead of Sunday's Big Game, Instacart...

at 05:29
A news report from Shenzhen Daily: Tafadzwa Mackenzie Kadere (Taf), a Shenzhen Global Communication Ambassador from the U.K.,...

at 01:54
AEON, the next-generation payment protocol pioneering payment abstraction, has partnered with Viction, a blockchain platform redefining scalability and interoperability through its World Wide Chain (WWC). This collaboration enables AEON Pay to...

at 00:55
Payment protocol AEON has announced a strategic partnership with Viction, a high-performance blockchain platform. AEON Pay now supports the use of Viction ecosystem's native assets ($VIC, $C98, and stablecoins) in offline payment scenarios. Users...

7 fév 2025
Report on how AI is redefining market landscape - The global events industry market  size is estimated to grow by USD 1.07 trillion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of  13.5%  during the forecast...



News published on and distributed by: